Folic acid improves arterial endothelial function in adults with hyperhomocystinemia

Journal of the American College of Cardiology

Volumn 34, Issue 7, 1999, Pages 2002-2006

  Woo, Kam S ^c   Chook, Ping ^c   Lolin, Yvette I ^a   Sanderson, John E ^c   Metreweli, Con ^c   Celermajer, David S ^b  

^a KENT AND SUSSEX HOSPITAL   (United Kingdom)

^b UNIVERSITY OF SYDNEY   (Australia)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

FOLIC ACID; HOMOCYSTEINE;

ADULT; ARTERY DILATATION; ARTERY ENDOTHELIUM; ARTICLE; ATHEROSCLEROSIS; BLOOD VESSEL FUNCTION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET SUPPLEMENTATION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; FOLIC ACID BLOOD LEVEL; HUMAN; HYPERHOMOCYSTEINEMIA; MALE; ORAL DRUG ADMINISTRATION; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR;

ADMINISTRATION, ORAL; ADULT; AGED; ARTERIOSCLEROSIS; BRACHIAL ARTERY; CHOLESTEROL; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; ENDOTHELIUM, VASCULAR; FEMALE; FOLIC ACID; HEMATINICS; HOMOCYSTEINE; HUMANS; HYPERHOMOCYSTEINEMIA; MALE; MIDDLE AGED; OBSERVER VARIATION; TREATMENT OUTCOME; VASODILATION;

EID: 0033405725     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(99)00469-6     Document Type: Article

References (29)

1. Malinow M.R. Hyperhomocysteinemia a common and easily reversible risk factor for occlusive atherosclerosis . Circulation. 81:1990;2004-2006.
2. Mayer E.L., Jacobsen D.W., Robinson K. Homocysteine and coronary atherosclerosis. J Am Coll Cardiol. 27:1996;517-527.
3. Stamler J.S., Osborne J.A., Jaraki O., Rabbani L.E., Mullins M., Singel D., Loscalzo J. Adverse vascular effects of homocysteine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen. J Clin Invest. 91:1993;308-318.
4. Lentz S.R., Sobey C.G., Piegors D.J., Bhopatkar M.Y., Faraci F.M., Malinow M.R., Heistad D.D. Vascular dysfunction in monkeys with diet-induced hyperhomocyst(e)inemia. J Clin Invest. 98:1996;24-29.
5. Woo K.S., Chook P., Lolin Y.I., et al. Hyperhomocysteinemia is a risk factor for arterial endothelial dysfunction in humans. Circulation. 96:1997;2542-2544.
6. Tawakol A., Omland T., Gerhard M., Wu J.T., Creager M.A. Hyperhomocyst(e)inemia is associated with impaired endothelial-dependent vasodilatation in humans. Circulation. 95:1997;1119-1121.
7. Chambers J.C., Obeid O., McGregor A., Powell-Tuck J., Boustead L., Kooner J.S. The relationship between hyperhomocysteinaemia and endothelial dysfunction is concentration-dependent, and present even at physiological levels. Circulation. 98:1998;I192.
8. Ross R. The pathogenesis of atherosclerosis a perspective for the 1990s . Nature. 362:1993;801-809.
9. Sorensen K.E., Celermajer D.S., Spiegelhalter D.J., et al. Noninvasive measurement of human endothelium-dependent arterial responses accuracy and reproducibility . Br Heart J. 74:1995;247-253.
10. Shipchandler M.T., Moore E.G. Rapid, fully automated measurement of plasma homocyst(e)ine with the Abbott IMX analyzer. Clin Chem. 41:1995;991-994.
11. Woo KS, Lolin YI, Celermajer DS. Hyperhomocyst(e)inemia is a risk factor for arterial endothelial dysfunction in humans. Circulation 1999. In Press.
12. Joannides R., Haefeli W.E., Linder L., Richard V., Bakkali E.H., Thuillez C., Luscher T.F. Nitric-oxide is responsible for flow-dependent dilatation of human peripheral conduit arteries in vivo. Circulation. 91:1995;1314-1319.
13. Anderson T.J., Uehata A., Gerhard M.D., et al. Close relationship of endothelial cell function in the human coronary and peripheral circulations. J Am Coll Cardiol. 26:1995;1235-1241.
14. Neunteufl T., Katzenschlager R., Hassan A., et al. Systemic endothelial function is related to the extent and severity of coronary artery disease. Atherosclerosis. 129:1997;111-118.
15. Hochberg Y. A sharper Bonferroni procedure for multiple tests of significance. Biometrika. 75:1988;800-802.
16. Celermajer D.S., Sorensen K., Ryalls M., Robinson J., Thomas O., Leonard J.V., Deanfield J.E. Impaired endothelial function occurs in the systemic arteries of children with homozygous homocystinuria but not in their heterozygous parents. J Am Coll Cardiol. 22:1993;854-858.
17. Lentz S.R., Sadler J.E. Inhibition of thrombomodulin surface expression and protein C activation by the thrombogenic agent homocysteine. J Clin Invest. 88:1991;1906-1914.
18. Starkebaum G., Harlan J.M. Endothelial cell injury due to copper-catalyzed hydrogen peroxide formation from homocysteine. J Clin Invest. 77:1986;1370-1376.
19. Cooke J.P., Tsao P.S. Is NO an endogenous anti-atherogenic molecule? Arterioscler Thromb Vasc Biol. 14:1994;653-655.
20. Malinow M.R., Nieto F.J., Kruger W.D., et al. The effects of folic acid supplementation on plasma total homocysteine are modulated by multivitamin use and methylenetetrahydrofolate reductase genotypes. Arterioscler Thromb Vasc Biol. 17:1997;1157-1162.
21. Landgren E., Israelsson B., Lindgren A., Hultberg B., Andersson A., Brattström L. Plasma homocysteine in acute myocardial infarction homocysteine-lowering effect of folic acid . J Intern Med. 237:1995;381-388.
22. Ubbink J.B. The role of vitamins in the pathogenesis and treatment of hyperhomocyst(e)inaemia. J Inherit Metab Dis. 20:1997;316-325.
23. Verhaar M.C., Wever R.M.F., Kastelein J.J.P., van Dam T., Koomans H.A., Rabelink T.J. 5-Methyltetrahydrofolate, the active form of folic acid, restores endothelial function in familial hypercholesterolemia. Circulation. 97:1998;237-241.
24. Clarkson P., Adams M.R., Powe A.J., et al. Oral L-arginine improves endothelium-dependent dilation in hypercholesterolemic young adults. J Clin Invest. 97:1996;1989-1994.
25. Levine G.N., Frei B., Kouloukis S.N., Gerhard M.O., Keaney J.F.J., Vita J.A. Ascorbic acid reverses endothelial vasomotor dysfunction in patients with coronary artery disease. Circulation. 93:1996;1107-1113.
26. O'Driscoll G., Green D., Taylor R.R. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation. 95:1997;1126-1131.
27. Treasure C.B., Klein J.L., Weintraub W.S., et al. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med. 332:1995;481-487.
28. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease the Scandinavian Simvastatin Survival Study (4S) . Lancet. 344:1994;1383-1389.
29. Murakami T., Mizuno S., Kaku B. Clinical morbidities in subjects with Doppler-evaluated endothelial dysfunction of coronary artery. (abstr) J Am Coll Cardiol. 31:1998;419A.